FUTURE-PROSPECTS IN ANTIVIRAL THERAPY

被引:3
作者
WILTINK, EHH
机构
[1] Department of Pharmacy, Academic Medical Centre, AZ Amsterdam, 1105
关键词
ANTIVIRAL DRUGS; FUTURE PROSPECTS;
D O I
10.1007/BF01962549
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Two important stumbling blocks to the development of effective and nontoxic antiviral drugs are the intracellular localization of the virus and the fact that a virus uses host cell functions to multiply. Therefore, new antiviral drugs must act on a virus-specific function. Most currently available useful antiviral drugs are the result of compound screening of large numbers of possible agents. Advances in our understanding of the molecular biology and biochemistry of the viral multiplication cycle and new laboratory techniques for determining the molecular sites of action have now made it possible to develop and screen new antiviral drugs in a more purposeful manner. Another possible option in antiviral therapy is combination therapy using drugs that enhance the therapeutic effect or diminish side-effects. The most promising new antiviral drugs are discussed according to the different steps they affect in the viral multiplication process. Combination therapy is also reviewed.
引用
收藏
页码:268 / 274
页数:7
相关论文
共 28 条
  • [1] ORAL DEXTRAN SULFATE (UA001) IN THE TREATMENT OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND AIDS-RELATED COMPLEX
    ABRAMS, DI
    KUNO, S
    WONG, R
    JEFFORDS, K
    NASH, M
    MOLAGHAN, JB
    GORTER, R
    UENO, R
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 110 (03) : 183 - 188
  • [2] STRUCTURAL-ANALYSIS OF A SERIES OF ANTIVIRAL AGENTS COMPLEXED WITH HUMAN RHINOVIRUS-14
    BADGER, J
    MINOR, I
    KREMER, MJ
    OLIVEIRA, MA
    SMITH, TJ
    GRIFFITH, JP
    GUERIN, DMA
    KRISHNASWAMY, S
    LUO, M
    ROSSMANN, MG
    MCKINLAY, MA
    DIANA, GD
    DUTKO, FJ
    FANCHER, M
    RUECKERT, RR
    HEINZ, BA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (10) : 3304 - 3308
  • [3] BALDWIN GC, 1989, BLOOD, V74, P1673
  • [4] DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY
    CAPON, DJ
    CHAMOW, SM
    MORDENTI, J
    MARSTERS, SA
    GREGORY, T
    MITSUYA, H
    BYRN, RA
    LUCAS, C
    WURM, FM
    GROOPMAN, JE
    BRODER, S
    SMITH, DH
    [J]. NATURE, 1989, 337 (6207) : 525 - 531
  • [5] CARTER WA, 1987, LANCET, V1, P1286
  • [6] A PILOT-STUDY OF LOW-DOSE ZIDOVUDINE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    COLLIER, AC
    BOZZETTE, S
    COOMBS, RW
    CAUSEY, DM
    SCHOENFELD, DA
    SPECTOR, SA
    PETTINELLI, CB
    DAVIES, G
    RICHMAN, DD
    LEEDOM, JM
    KIDD, P
    COREY, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) : 1015 - 1021
  • [7] HIGH-CONCENTRATIONS OF RECOMBINANT SOLUBLE CD4 ARE REQUIRED TO NEUTRALIZE PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES
    DAAR, ES
    LI, XL
    MOUDGIL, T
    HO, DD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) : 6574 - 6578
  • [8] A RANDOMIZED CONTROLLED TRIAL OF A REDUCED DAILY DOSE OF ZIDOVUDINE IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME
    FISCHL, MA
    PARKER, CB
    PETTINELLI, C
    WULFSOHN, M
    HIRSCH, MS
    COLLIER, AC
    ANTONISKIS, D
    HO, M
    RICHMAN, DD
    FUCHS, E
    MERIGAN, TC
    REICHMAN, RC
    GOLD, J
    STEIGBIGEL, N
    LEOUNG, GS
    RASHEED, S
    TSIATIS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) : 1009 - 1014
  • [9] INCREASED EFFICACY OF GANCICLOVIR IN COMBINATION WITH FOSCARNET AGAINST CYTOMEGALOVIRUS AND HERPES-SIMPLEX VIRUS TYPE-2 INVITRO AND INVIVO
    FREITAS, VR
    FRASERSMITH, EB
    MATTHEWS, TR
    [J]. ANTIVIRAL RESEARCH, 1989, 12 (04) : 205 - 212
  • [10] SYNERGISTIC ACTIVITY OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND 3'-AZIDO-3'-DEOXYTHYMIDINE AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS INVITRO
    HAMMER, SM
    GILLIS, JM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) : 1046 - 1050